As UEGW 2020 will be a virtual congress this year we’d like to draw your attention to some top-quality, peer-reviewed papers. These are both NEW 2020 and formerly purchased papers by Takeda some of which still have active licenses to be utilised. Supplied as Trustrack Links they can be hosted on your website, sent out in mailings embedded in digital ad campaigns or even integrated into Virtual Congress opportunities.
If you are interested in a quote for these or any other papers please CONTACT US.
The Lancet: Gastro & Hepatology • Author: Feagan et al • Published: May 2018 LIVE TRUSTRACK LICENSE AVAILABLE NOW - Expires Feb 2021 Rapid Response to Vedolizumab Therapy in Biologic-Naïve Patients With Inflammatory Bowel Diseases (GEMINI ANALYSIS).
Gastroenterology • Author: Lowenberg et al • Published: June 2019 LIVE TRUSTRACK LICENSE AVAILABLE NOW - Expires Feb 2021 Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease (LOVE-CD).
New England Journal of Medicine • Author: Sands et al • Published: September 2019 LIVE TRUSTRACK LICENSE AVAILABLE NOW - Expires Feb 2021 Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Gastroenterology • Author: Panes et al • Published: April 2018 USED AT UEGW 2019 WITH TRUSTRACK Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease.
Journal of Crohns & Colitis • Author: Lightner et al • Published: October 2017 USED AT UEGW 2019 WITH TRUSTRACK Mesenchymal Stem Cell Injections for the Treatment of Perianal Crohn's Disease: What We Have Accomplished and What We Still Need to Do.
Jnl of Gastrointestinal Surgery • Author: Georgiev-Hristov et al • Published: July 2018 USED AT UEGW 2019 WITH TRUSTRACK A Step-By-Step Surgical Protocol for the Treatment of Perianal Fistula with Adipose-Derived Mesenchymal Stem Cells.
Gastroenterology • Author: Danese et al • Published: October 2019 USED AT UEGW 2019 WITH TRUSTRACK Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn’s Disease (VERSIFY).
NEW + OUP 10% DISCOUNT on all ePrint Orders confirmed by 31st October Journal of Crohns & Colitis • Author: Martin A et al • Published: January 2020 Maintenance of remission among patients with inflammatory bowel disease after vedolizumab discontinuation: a multicentre cohort study.
NEW + OUP 10% DISCOUNT on all ePrint Orders confirmed by 31st October Journal of Crohns & Colitis • Author: Scott FI et al • Published: January 2020 Identification of the most cost effective position of vedolizumab among the available biologic drugs for the treatment of ulcerative colitis.
NEW + OUP 10% DISCOUNT on all ePrint Orders confirmed by 31st October Journal of Crohns & Colitis • Author: Coletta MJ et al • Published: February 2020 Immunological variables associated with clinical and endoscopic response to vedolizumab in patients with inflammatory bowel diseases.
NEW + OUP 10% DISCOUNT on all ePrint Orders confirmed by 31st October Journal of Crohns & Colitis • Author: Vermiere S et al • Published: February 2020 Vedolizumab Efficacy, Safety, and Pharmacokinetics with Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients with Crohn's Disease or Ulcerative Colitis.
NEW + OUP 10% DISCOUNT on all ePrint Orders confirmed by 31st October Journal of Crohns & Colitis • Author: Parambir SD et al • Published: July 2020 Early Intervention With Vedolizumab on Longer Term Surgery Rates in Crohn's Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programs.
